Allegheny General Hospital, Allegheny Valley Hospital and West Penn Hospital, all part of the Allegheny Health Network, are among a select group of medical centers in the country, including just 57 in Pennsylvania, to be lauded as Top Performers on Key Quality Measures by The Joint Commission, the leading accreditor of health care organizations
Arch Biopartners Inc has now completed a Clinical Development Plan to prepare a human trial for MetaMx, the Company's brain tumour targeting technology. Arch Biopartners management intends to have these tasks completed in 2015.. A pre-Investigational New Drug meeting with the Food and Drug Administration is planned upon availability of toxicology d
Avaxia Biologics reported that the US Food and Drug Administration granted Orphan Drug Designation to AVX-470 for the treatment of pediatric ulcerative colitis. According to a company release, AVX-470 is a gut-targeted anti- TNF antibody, which earlier this year successfully completed a Phase 1 b clinical trial in adults with active ulcerative coli
Becton, Dickinson and Company is a global medical technology company engaged principally in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general...
By a News Reporter-Staff News Editor at Biotech Week BioCardia , Inc., a leader in cardiovascular regenerative medicine, announced that the U.S. Food and Drug Administration has accepted the Company's application to begin a Phase III clinical trial of its bone marrow-derived CardiAMP Therapy for heart failure. Dr. Pepine is Professor of Medicin
The Canadian regulatory authority, Health Canada has given approval to Beximco Pharmaceuticals Ltd for good manufacturing practices. Beximco became the first Bangladeshi firm to get this accreditation from Health Canada. Managing Director Nazmul Hassan added, " Canada is an important market for Beximco Pharma and this approval marks a significant..
By a News Reporter-Staff News Editor at Biotech Week Cell Source, Inc. an immunotherapy and regenerative medicine company, announced its Megadose Drug Combination has been cleared for human clinical trials in Italy. Cell Source's proprietary Megadose Drug Combination is expected to increase bone marrow transplantation success and survival.
Nov. 26 The day after her 61st birthday, Renee Oakes received a letter she quickly regretted opening. As the retired Erlanger Health System nurse unfolded the memo, she learned that the retiree health insurance she relies on would be canceled altogether on Dec. 31. "With the heavy economic burdens Erlanger Health System has faced, it has become
The drug has been taken by more than 100,000 patients within just 18 months of the U.S. launch, Scangos said. The patient died of progressive multifocal leukoencephalopathy, or PML, after taking Tecfidera for more than four years in a long-term study. The U.S. Food and Drug Administration on Tuesday ordered that new labeling information that descri
Florida Hospital Tampa is being recognized as a 2013 Top Performer on Key Quality Measures by The Joint Commission, the leading accreditor of health care organizations in the United States. In addition, we've made an investment in our community by building a new ER and ICU Tower. Just another example of how Florida Hospital Tampa is elevating healt
Based on its recent analysis of the positron emission tomography imaging industry, Frost& Sullivan recognizes Philips Healthcare with the 2014 North America Frost& Sullivan Award for Technology Innovation Leadership. Philips Healthcare launched the industry's first digital PET/computed tomography system when it introduced the Vereos PET/CT system
There are at least two important reasons why companies are sponsoring health insurance for their employees. Healthy employees reduce absenteeism and reduction of productivity. Health insurance coverage provided to employees as part of the compensation program increases the willingness of qualified human resources to join and maintain existing...
A coalition of leading web-based health insurance brokers announced today the formation of the Association of Web-Based Health Insurance Brokers. AWHIB founding members include four prominent web-brokers: eHealth, GetInsured, GoHealth, and Towers Watson. Shane Cruz, the Chief Technology Officer of GoHealth, will serve as AWHIB's President and state
By a News Reporter-Staff News Editor at Biotech Week Highland Therapeutics Inc., a pharmaceutical company, announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent application owned by the Company's wholly owned subsidiary, Ironshore Pharmaceuticals& Development, Inc.. "A strong intellectual property esta
iCAD, Inc., an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced that Company management will participate in the upcoming LD MICRO Main Event Micro-Cap Growth Conference taking place from December 2-4, 2014 in Los Angeles.
Endo International plc declared that the purchase of rights to Natesto, the first and only testosterone nasal gel for replacement therapy in adult males diagnosed with hypogonadism, from Trimel BioPharma SRL, a wholly-owned subsidiary of Trimel Pharmaceuticals Corporation. Natesto was sanctioned by the U.S. Food and Drug Administration in May of 20
Boehringer Ingelheim reported that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion for nintedanib for the treatment of patients with idiopathic pulmonary fibrosis. According to a media release, results from the Phase III INPULSIS trials, published in the New England Journal of Medici
Patented pharmaceuticals diffuse across international borders slowly, and sometimes not at all. By Iain M. Cockburn, Jean O. Lanjouw and Mark Schankerman. Lovastatin, a first-in-class blockbuster cholesterol drug, became commercially available in Egypt in 1999 12 years after it was first approved for sale by the US Food and Drug Administration.
THOUSAND OAKS- Amgen Inc. and AstraZeneca plc's phase III trial of psoriasis drug candidate Brodalumab has met its primary endpoint of achieving total clearance of skin disease when compared with placebo as well as Janssen Biotech Inc.' s approved drug Stelara. Brodalumab is being co-developed by Amgen and AstraZeneca. Cologuard is the first and on
RepliCel Life Sciences Inc., a clinical stage regenerative medicine company focused on the development of autologous cell therapies, today announced its operational and financial results for the third quarter ended September 30, 2014. Completed pre-clinical regulatory meetings with German authorities for Phase 1 aged and sun damaged skin program-
Recently published research from Global Markets Direct, " N30 Pharmaceuticals- Product Pipeline Review- 2014", is now available at Fast Market ResearchBoston, MA 11/26/2014 Global Markets Direct's,' N30 Pharmaceuticals- Product Pipeline Review- 2014', provides an overview of the N30 Pharmaceuticals's pharmaceutical research and development fo
Revive Therapeutics Ltd. is pleased to announce that the U.S. Food and Drug Administration has accepted the Company's Investigational New Drug Application to commence a clinical trial for REV-002 for the treatment of gout. FDA and its announcement that it has signed a material transfer agreement with a global pharmaceutical company headquartered in
In addition, the organization has announced that it has selected Allscripts TouchWorks EHR ambulatory solution to support care and patient management efforts for Robert Wood Johnson Physician Enterprise care network. x0D;. "We believe this is a tremendous opportunity for our organization to utilize a high-performing EHR to create a single, pa
According to a release, the SCAN-UCLA Best Practices Summit was sponsored by the not-for-profit SCAN Health Plan and the UCLA Multicampus Program in Geriatric Medicine and Gerontology and focused on best practices in two main areas- multiple chronic disease management and end-of-life care. "In order to enrich the patient experience, improve health
By a News Reporter-Staff News Editor at Biotech Week Law Offices of Howard G. Smith announces that it is investigating potential claims on behalf of investors of Sarepta Therapeutics, Inc.. The investigation is related to the Company's October 27, 2014, announcement of a regulatory update concerning the Company's discussions with the U.S. Food an